Novel role of the CXC chemokine receptor 3 in inflammatory response to arterial injury: Involvement of mTORC1

Circulation Research

Volumn 104, Issue 2, 2009, Pages 189-200

  Schwarz, Johannes B K ^a   Langwieser, Nicolas ^a   Langwieser, Nicole N ^a   Bek, Martin J ^b   Seidl, Stefan ^c   Eckstein, Hans Henning ^c   Lu, Bao ^d   Schömig, Albert ^a   Pavenstädt, Hermann ^b   Zohlnhöfer, Dietlind ^a,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Chemokines; Inflammation; Intimal hyperplasia; MTORC1

Indexed keywords

CHEMOKINE RECEPTOR CCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MAMMALIAN TARGET OF RAPAMYCIN; REACTIVE OXYGEN METABOLITE; CARDIOVASCULAR AGENT; CARRIER PROTEIN; CHEMOKINE RECEPTOR CXCR3; CXCL9 PROTEIN, MOUSE; CXCR3 PROTEIN, MOUSE; DRUG DERIVATIVE; EVEROLIMUS; FRAP1 PROTEIN, MOUSE; PHOSPHOTRANSFERASE; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTERY INJURY; ARTICLE; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPERPLASIA; IMMUNE SYSTEM; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; VASCULAR SURGERY; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMOTAXIS; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMORAL ARTERY; GENETICS; IMMUNOLOGY; INJURY; LEUKEMIA CELL LINE; METABOLISM; MOUSE MUTANT; PATHOLOGY; SIGNAL TRANSDUCTION; TIME;

ANIMALS; APOPTOSIS; CARDIOVASCULAR AGENTS; CARRIER PROTEINS; CELL PROLIFERATION; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CHEMOTAXIS; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; HEMATOPOIETIC STEM CELLS; HUMANS; HYPERPLASIA; INFLAMMATION; JURKAT CELLS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); REACTIVE OXYGEN SPECIES; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION; SIROLIMUS; TH1 CELLS; TIME FACTORS;

EID: 59849106844     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.182683     Document Type: Article

References (36)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002; 105:2974-2980. (Pubitemid 34693829)
3. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394:200-203.
4. Weber C. Chemokines take centre stage in vascular biology. Thromb Haemost. 2007;97:685-687.
5. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost. 2007;97:714-721.
6. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, Luster AD. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest. 1999;104: 1041-1050.
7. Xie JH, Nomura N, Lu M, Chen SL, Koch GE, Weng Y, Rosa R, Di Salvo J, Mudgett J, Peterson LB, Wicker LS, DeMartino JA. Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J Leukoc Biol. 2003;73:771-780.
8. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, Colvin RA, Kihara S, Funahashi T, Luster AD, Libby P. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res. 2008;102:218-225.
9. van Wanrooij EJ, de Jager SC, van Es T, de Vos P, Birch HL, Owen DA, Watson RJ, Biessen EA, Chapman GA, van Berkel TJ, Kuiper J. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008;28: 251-257.
10. Wendt MK, Drury LJ, Vongsa RA, Dwinell MB. Constitutive CXCL12 expression induces anoikis in colorectal carcinoma cells. Gastroenterology. 2008;135:508-517.
11. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio M. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest. 2001; 107:53-63.
12. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187:129-134.
13. Bek MJ, Reinhardt HC, Fischer KG, Hirsch JR, Hupfer C, Dayal E, Pavenstadt H. Up-regulation of early growth response gene-1 via the CXCR3 receptor induces reactive oxygen species and inhibits Na+/K +-ATPase activity in an immortalized human proximal tubule cell line. J Immunol. 2003;170:931-940.
14. Kaur S, Lal L, Sassano A, Majchrzak-Kita B, Srikanth M, Baker DP, Petroulakis E, Hay N, Sonenberg N, Fish EN, Platanias LC. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem. 2007;282:1757-1768.
15. Murooka TT, Rahbar R, Platanias LC, Fish EN. CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/ 4E-BP1. Blood. 2008;111:4892-4901.
16. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471-484.
17. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15:807-826.
18. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349:1315-1323.
19. Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andres V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis. 2004;172:31-38.
20. Nuhrenberg TG, Langwieser N, Schwarz JB, Hou Y, Frank P, Sorge F, Matschurat S, Seidl S, Kastrati A, Schomig A, Clauss MA, Zohlnhofer D. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. Cardiovasc Res. 2008;77:580-589.
21. Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S, Aoyagi T, Imai Y, Kurihara H, Kimura K, Omata M, Makuuchi M, Hirata Y, Nagai R. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol. 2000;32:2097-2104.
22. Jinquan T, Anting L, Jacobi HH, Glue C, Jing C, Ryder LP, Madsen HO, Svejgaard A, Skov PS, Malling HJ, Poulsen LK. CXCR3 expression on CD34( + ) hemopoietic progenitors induced by granulocyte-macrophage colony-stimulating factor. II. Signaling pathways involved. J Immunol. 2001;167:4405-4413.
23. Khurana R, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla-Herttuala S, Ferrara N, Martin JF, Zachary I, Simons M. Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation. 2004;110:2436-2443.
24. Hansson GK, Holm J, Holm S, Fotev Z, Hedrich HJ, Fingerle J. T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci U S A. 1991;88:10530-10534.
25. Remskar M, Li H, Chyu KY, Shah PK, Cercek B. Absence of CD40 signaling is associated with an increase in intimal thickening after arterial injury. Circ Res. 2001;88:390-394.
26. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, Smiley ST, Ling M, Gerard NP, Gerard C. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med. 2000;192:1515-1520.
27. Werner N, Priller J, Laufs U, Endres M, Bohm M, Dirnagl U, Nickenig G. Bone marrow-derived progenitor cells modulate vascular reendothe-lialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002;22:1567-1572.
28. Jiang S, Walker L, Afentoulis M, Anderson DA, Jauron-Mills L, Corless CL, Fleming WH. Transplanted human bone marrow contributes to vascular endo-thelium. Proc Natl Acad Sci U S A. 2004;101:16891-16896.
29. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403-409.
30. Sahara M, Sata M, Matsuzaki Y, Tanaka K, Morita T, Hirata Y, Okano H, Nagai R. Comparison of various bone marrow fractions in the ability to participate in vascular remodeling after mechanical injury. Stem Cells. 2005;23:874-878.
31. Schober A, Knarren S, Lietz M, Lin EA, Weber C. Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation. 2003;108:2491-2497.
32. Wang Y, Bai Y, Qin L, Zhang P, Yi T, Teesdale SA, Zhao L, Pober JS, Tellides G. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res. 2007;101:560-569.
33. Perez de Obanos MP, Lopez-Zabalza MJ, Arriazu E, Modol T, Prieto J, Herraiz MT, Iraburu MJ. Reactive oxygen species (ROS) mediate the effects of leucine on translation regulation and type I collagen production in hepatic stellate cells. Biochim Biophys Acta. 2007;1773:1681-1688.
34. Legare JF, Issekutz T, Lee TD, Hirsch G. CD8+ T lymphocytes mediate destruction of the vascular media in a model of chronic rejection. Am J Pathol. 2000;157:859-865.
35. Zohlnhofer D, Nuhrenberg TG, Neumann FJ, Richter T, May AE, Schmidt R, Denker K, Clauss MA, Schomig A, Baeuerle PA. Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. Mol Pharmacol. 2004;65: 880-889.
36. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847-858.